Main Content


Study title

A double-blind, placebo-controlled phase 2 trial of Seribantumab plus Fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positve (HRG+), HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

  • Principal Investigator: Dr. Shou Ching Tang


This study is evaluating an experimental drug for postmenopausal women whose breast cancer has progressed after prior therapy.

Who can participate

Those eligible to participate in this study include:

  • Women who are 18 years or older with metastatic breast cancer

For more information

  • Sandra Powe
    University of Mississippi Medical Center 
    2500 N. State St. 
    Jackson MS 39216 
    (601) 984-1965
  • IRB Number: 2018-0090